Should the transaction complete, J&J will inherit Atraverse's radiofrequency system for simplifying access to the heart's left atrium.
CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including electrophysiology and Watchman.
Discover the design and engineering story behind the company’s OmniaSecure defibrillation lead.
This new pulse sequence marks the next evolution of J&J's Varipulse Platform and is designed to improve procedural efficiency while reinforcing its established safety and effectiveness profile.
The medical device giant acquired an AI-powered coronary assessment company for $585M and led a $100M strategic round for a pulmonary hypertension therapy pioneer.
Addressing key clinical challenges: Adopting an eccentric structural design to reduce the difficulty of surgical operation and the risk of left ventricular outflow tract obstruction, while achieving stable anchoring performance and good hemodynamic performance.
Clinical data demonstrate low mortality, fewer complications and faster patient recovery with a minimally invasive alternative to open-heart surgery.
Boston Scientific's recall highlights high impedance risks in medical devices. Understand the meaning, causes, and possible solutions.
Trivia Tuesday: Ripped from the headlines 34 years before its time, what show eerily predicted Boston Scientific’s pacemaker battery problem?
